drugset
drugset / Trial / NCT05601752

ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)

NCT05601752 ↗

Phase 2 Active not recruiting 66 enrolled USWM CT, LLC GOG Foundation · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a phase 2, open-label, randomized, non-comparative clinical trial to evaluate the clinical outcome of ADP A2M4CD8 as monotherapy and in combination treatment with nivolumab in human leukocyte antigen (HLA) A2+ subjects with recurrent ovarian cancer positive for MAGE-A4.

Timeline

Start
2023-06-26
Primary completion
2026-08-12
Completion
2026-08-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Autologous genetically modified ADP-A2M4CD8 cells Cell therapy — —
Subject Nivolumab Monoclonal antibody 480 mg Intravenous

Indications

ovarian cancer